At a glance
- Originator Valeant Pharmaceuticals International
- Developer Sanofi-Synthelabo; Valeant Pharmaceuticals International
- Class Antineoplastics; Purine nucleosides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies